News Alnylam joins three-way contest in ATTR cardiomyopathy Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.
News BridgeBio gets EU nod for ATTR cardiomyopathy drug BridgeBio and Bayer are poised to challenge Pfizer's Vyndaqel in the EU after acoramidis gets a green light for ATTR cardiomyopathy.
News BridgeBio poised to challenge Pfizer after Attruby approval BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer
News Flagship joins three biotechs together to form Etcelera Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.